TSRO Key Stats
- TESARO to Present at the Barclays Global Healthcare Conference noodls 03/06 08:45 ET
- 4:17 pm Tesaro reports Q4 loss of ($0.72)/share, no revs Yahoo 02/20 01:56 ET
- TESARO's CEO Discusses Q4 2013 Results - Earnings Call Transcript Seeking Alpha 02/19 21:19 ET
- TESARO Announces Fourth-Quarter and Full-Year 2013 Operating Results noodls 02/19 17:10 ET
- Tesaro (TSRO) Posts Q4 Loss of 72c/Share Street Insider 02/19 16:19 ET
- TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Yahoo 02/19 16:08 ET
- Q4 2013 TESARO Inc Earnings Release - After Market Close Yahoo 02/19 07:07 ET
- TESARO to Announce Fourth Quarter 2013 Financial Results on February 19, 2014 noodls 02/07 09:16 ET
- TESARO to Present at Two Upcoming Investment Conferences noodls 02/05 16:27 ET
- TESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits Yahoo 02/04 16:24 ET
TSRO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tesaro is up 23.71% over the last year vs S&P 500 Total Return up 24.21%, United Therapeutics up 64.62%, and Cubist Pharmaceuticals up 61.62%.
Balance Sheet View Statement
Pro Ratings for TSRO
Pro Report PDF for TSRO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TSRO Pro Report PDF
Pro Strategies Featuring TSRO
Did Tesaro make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Massachusetts
- Incorporation Country: United States
- Incorporation State/Province: Delaware
TESARO, Inc is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.